Issue Date: September 20, 2010
Acceleron, Shire Ink Collaboration
Acceleron Pharma and Shire have formed a joint development and commercialization agreement under which Shire will obtain rights outside the U.S. to a range of Acceleron molecules targeting activin receptor type IIB pathway, which helps regulate skeletal muscle growth. The collaboration will initially investigate ACE-031, currently in Phase II clinical trials for patients with Duchenne muscular dystrophy (DMD). Shire will make an up-front payment of $45 million to Acceleron, as well as possible milestone payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society